Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 10, 2014, Pages 1580-1585

  Sánchez Guijo, Fermín ^a,b,c   Caballero Velázquez, Teresa ^d   López Villar, Olga ^a,b,c   Redondo, Alba ^a,b,c   Parody, Rocío ^d   Martínez, Carmen ^e   Olavarría, Eduardo ^f   Andreu, Enrique ^c,g   Prósper, Felipe ^c,g   Díez Campelo, María ^a   Regidor, Carmen ^h   Villaron, Eva ^a,b,c   López Corral, Lucía ^a   Caballero, Dolores ^a   Cañizo, María Consuelo del ^a,b,c   Pérez Simon, José Antonio ^d  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b ISCIII)   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f Universidad Pública de Navarra   (Spain)

^g UNIVERSITY CLINIC OF NAVARRA   (Spain)

^h HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Graft versus host disease (GVHD); Mesenchymal stromal cells (MSC)

Indexed keywords

ALEMTUZUMAB; BECLOMETASONE DIPROPIONATE; BORTEZOMIB; BUDESONIDE; CYCLOSPORIN; GLYCERYL TRINITRATE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PSORALEN; RAPAMYCIN; TACROLIMUS; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; STEROID;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ARTICLE; BACTERIAL INFECTION; BODY WEIGHT; CELL THERAPY; CLINICAL ARTICLE; CYTOMEGALOVIRUS; DRUG TREATMENT FAILURE; ERYTHROCYTE TRANSFUSION; FEMALE; GRAFT VERSUS HOST REACTION; HEART MUSCLE ISCHEMIA; HUMAN; INVASIVE ASPERGILLOSIS; MALE; MESENCHYMAL STROMA CELL; MESENCHYMAL STROMA CELL TRANSPLANTATION; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; TREATMENT RESPONSE; VIRUS REACTIVATION; ACUTE DISEASE; ALLOTRANSPLANTATION; CELL COUNT; CHEMISTRY; CLINICAL TRIAL; CRYOPRESERVATION; CYTOLOGY; DRUG RESISTANCE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; SURVIVAL; THROMBOCYTE; TREATMENT OUTCOME; UNRELATED DONORS;

ACUTE DISEASE; ADULT; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; CELL COUNT; CRYOPRESERVATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; PROSPECTIVE STUDIES; STEROIDS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS;

EID: 84912530901     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.06.015     Document Type: Article

References (36)

1. Choi S.W., Levine J.E., Ferrara J.L. Pathogenesis and management of graft-versus-host disease. Immunol Allergy Clin North Am 2010, 30:75-101.
2. Martin P.J., Inamoto Y., Flowers M.E., Carpenter P.A. Secondary treatment of acute graft-versus-host disease: a critical review. Biol Blood Marrow Transplant 2012, 18:982-988.
3. Dominici M., Le B.K., Mueller I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
4. Cook D., Genever P. Regulation of mesenchymal stem cell differentiation. Adv Exp Med Bio 2013, 786:213-229.
5. Shi M., Liu Z.W., Wang F.S. Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin Exp Immunol 2011, 164:1-8.
6. Tabera S., Perez-Simon J.A., Diez-Campelo M., et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica 2008, 93:1301-1309.
7. Galipeau J. The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?. Cytotherapy 2013, 15:2-8.
8. Perez Simon J.A., Lopez-Villar O., Andreu E.J., et al. Mesenchymal stem cells expanded invitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. Haematologica 2011, 96:1072-1076.
9. Muntion S., Sanchez-Guijo F.M., Carrancio S., et al. Optimisation of mesenchymal stromal cells karyotyping analysis: implications for clinical use. Transfus Med 2012, 22:122-127.
10. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
11. Goldberg J.D., Giralt S. Assessing response of therapy for acute and chronic graft-versus-host disease. Expert Rev Hematol 2013, 6:103-107.
12. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
13. Perez-Ilzarbe M., Diez-Campelo M., Aranda P., et al. Comparison of exvivo expansion culture conditions of mesenchymal stem cells for human cell therapy. Transfusion 2009, 49:1901-1910.
14. Carrancio S., Lopez-Holgado N., Sanchez-Guijo F.M., et al. Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification. Exp Hematol 2008, 36:1014-1021.
15. Bernardo M.E., Cometa A.M., Pagliara D., et al. Exvivo expansion of mesenchymal stromal cells. Best Pract Res Clin Haematol 2011, 24:73-81.
16. Fekete N., Rojewski M.T., Furst D., et al. GMP-compliant isolation and large-scale expansion of bone marrow-derived MSC. PloS One 2012, 7:e43255.
17. Introna M., Lucchini G., Dander E., et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant 2014, 20:375-381.
18. von Bonin M., Stolzel F., Goedecke A., et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009, 43:245-251.
19. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
20. Ringden O., Uzunel M., Rasmusson I., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
21. Ball L.M., Bernardo M.E., Roelofs H., et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol 2013, 163:501-509.
22. Resnick I.B., Barkats C., Shapira M.Y., et al. Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). Am J Blood Res 2013, 3:225-238.
23. Martin P.J., Rizzo J.D., Wingard J.R., et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012, 18:1150-1163.
24. von Bahr L., Sundberg B., Lonnies L., et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 2012, 18:557-564.
25. Lucchini G., Dander E., Pavan F., et al. Mesenchymal stromal cells do not increase the risk of viral reactivation nor the severity of viral events in recipients of allogeneic stem cell transplantation. Stem Cells Int 2012, 2012:690236.
26. Srinivasan R., Chakrabarti S., Walsh T., et al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004, 124:777-786.
27. Alousi A.M., Weisdorf D.J., Logan B.R., et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009, 114:511-517.
28. Kim S.S. Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation. Ann Pharmacother 2007, 41:1436-1444.
29. Arai S., Margolis J., Zahurak M., et al. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002, 8:155-160.
30. Carpenter P.A., Pavlovic S., Tso J.Y., et al. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. JImmunol 2000, 165:6205-6213.
31. Massenkeil G., Rackwitz S., Genvresse I., et al. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2002, 30:899-903.
32. Miano M., Cuzzubbo D., Terranova P., et al. Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience. Bone Marrow Transplant 2009, 43:423-427.
33. Couriel D., Saliba R., Hicks K., et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004, 104:649-654.
34. Patriarca F., Sperotto A., Damiani D., et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004, 89:1352-1359.
35. Sanchez-Guijo F.M., Lopez-Villar O., Lopez-Anglada L., et al. Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation. Transfusion 2012, 52:1086-1091.
36. Yin F., Battiwalla M., Ito S., et al. Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses. Stem Cells 2014, 32:1278-1288.